ImmuPharma plc (LON:IMM – Get Free Report) shares fell 14.6% on Tuesday . The stock traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). 13,200,714 shares traded hands during trading, a decline of 53% from the average session volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Price Performance
The firm has a market cap of £13.33 million, a PE ratio of -320.00 and a beta of 1.53. The business’s fifty day moving average is GBX 1.48 and its 200-day moving average is GBX 1.66.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Transportation Stocks Investing
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
